Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia

Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL. To improve the induction remission rate, we modified the dose of idarubicin in the original Children's Cancer Group (CCG)-1884 protocol, and retrospecti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yoon, Jong Hyung, Park, Jeong Ah, Kim, Eun Kyung, Kang, Hyoung Jin, Shin, Hee Young, Ahn, Hyo Seop
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The Korean Academy of Medical Sciences 2009
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2672129/
https://ncbi.nlm.nih.gov/pubmed/19399271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2009.24.2.281
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak